Loading REGN detail
Loading ticker data...
Loading REGN detail
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Chart data unavailable
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Cache Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 43.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,548 shares of the biopharmaceutical company's stock after selling 2,752 shares during the period. Regeneron Pharmaceuticals
Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,434 shares of the biopharmaceutical company's stock, valued at approximately $3,422,000. Other large investors also recently added
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,619 shares of the biopharmaceutical company's stock after selling 2,519 shares during the quarter. Sovran Advisors LLC's holdings in Regeneron
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische
- TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados de 300 millones de pacientes e impulsar la investigación y el
Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,738 shares of the biopharmaceutical company's stock after acquiring an additional 10,235
Regeneron a l'opportunité unique de connecter des cohortes de données génomiques et protéomiques à grande échelle au réseau mondial de données de dossiers
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers TARRYTOWN, N.Y. and CAMBRIDGE, Mass.
Drugmaker Regeneron said on Thursday it expects to be excluded from a list of pharmaceutical companies that could face new tariffs from the U.S. government.
